Results from phase I clinical trial of the first drug to successfully inhibit the MYC protein, which drives many common cancers 01 / 11 / 22| Read More
Omomyc as the first MYC-targeted therapy to successfully complete a phase I clinical trial 28 / 10 / 22| Read More
TODAY in El Mundo: “Así avanza el fármaco español pionero en su estrategia contra el cáncer” 26 / 10 / 22| Read More
TODAY in La Vanguardia: “Èxit del primer assaig en pacients del fàrmac Omomyc contra el càncer” 26 / 10 / 22| Read More
MYC inhibition halts metastatic breast cancer progression by blocking tumor growth, invasion & seeding 21 / 02 / 22| Read More
PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial 06 / 05 / 21| Read More
Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board 07 / 01 / 21| Read More